Integra LifeSciences Holdings (IART)

Solvency ratios

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Debt-to-assets ratio 0.27 0.28 0.42 0.43 0.37 0.38 0.35 0.36 0.33 0.36 0.37 0.38 0.37 0.37 0.37 0.40 0.39 0.41 0.43 0.43
Debt-to-capital ratio 0.41 0.43 0.53 0.52 0.47 0.47 0.44 0.44 0.42 0.44 0.45 0.46 0.45 0.46 0.47 0.49 0.48 0.50 0.52 0.52
Debt-to-equity ratio 0.70 0.74 1.12 1.09 0.88 0.90 0.79 0.80 0.72 0.80 0.83 0.86 0.82 0.85 0.88 0.97 0.93 1.01 1.09 1.10
Financial leverage ratio 2.61 2.67 2.66 2.55 2.38 2.37 2.24 2.23 2.16 2.21 2.26 2.27 2.25 2.31 2.36 2.45 2.39 2.47 2.51 2.57

The solvency ratios of Integra LifeSciences Holdings reflect the company's ability to meet its long-term financial obligations.

1. Debt-to-assets ratio: This ratio measures the proportion of the company's assets financed by debt. Integra LifeSciences Holdings' debt-to-assets ratio has shown a decreasing trend over the quarters, indicating an improvement in the company's ability to finance its assets through equity rather than debt.

2. Debt-to-capital ratio: This ratio evaluates the company's financial leverage by comparing its total debt to its total capital (debt plus equity). Integra LifeSciences Holdings' debt-to-capital ratio has also been decreasing, which suggests a lower reliance on debt in its capital structure.

3. Debt-to-equity ratio: This ratio indicates the proportion of the company's financing that comes from creditors versus shareholders. The decreasing trend in Integra LifeSciences Holdings' debt-to-equity ratio signifies a reduction in financial risk and a stronger equity position.

4. Financial leverage ratio: This ratio measures the company's use of debt in its capital structure and its ability to meet interest payments. Integra LifeSciences Holdings' financial leverage ratio has generally decreased over the quarters, which implies a decreasing reliance on debt financing.

Overall, the decreasing trends in these solvency ratios suggest that Integra LifeSciences Holdings is effectively managing its debt levels, improving its financial stability, and enhancing its capacity to withstand economic challenges.

Coverage ratios

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Interest coverage 0.46 0.61 1.35 1.87 2.58 3.30 4.12 5.08 5.31 5.13 5.01 4.80 5.26 4.63 4.00 3.24 2.31 2.20 1.20 1.80

Integra LifeSciences Holdings has shown fluctuations in its interest coverage ratio over the period from March 31, 2020, to December 31, 2024. The interest coverage ratio, which indicates the company's ability to cover its interest expenses with its earnings before interest and taxes (EBIT), started at 1.80 on March 31, 2020, indicating that the company's earnings were 1.80 times its interest expense.

The ratio decreased to 1.20 on June 30, 2020, indicating a slight deterioration in the company's ability to cover its interest payments. However, from September 30, 2020, onwards, the interest coverage ratio showed a consistent improvement, reaching a peak of 5.31 on December 31, 2022. This trend suggests that Integra LifeSciences Holdings was able to generate more earnings relative to its interest expenses during this period.

Subsequently, there was a slight decline in the interest coverage ratio, reaching 0.46 on December 31, 2024. This sharp decrease indicates that the company's ability to cover its interest payments with its earnings significantly weakened by the end of 2024. A declining interest coverage ratio can raise concerns about the company's financial health and its ability to meet its debt obligations.

Overall, while Integra LifeSciences Holdings showed improvement in its interest coverage ratio from September 2020 to December 2022, the significant decline in the ratio towards the end of 2024 may warrant further investigation into the company's financial performance and debt management strategies.